KR20220166337A - 코로나비리대 감염을 치료하는데 사용하기 위한 앱타머 - Google Patents

코로나비리대 감염을 치료하는데 사용하기 위한 앱타머 Download PDF

Info

Publication number
KR20220166337A
KR20220166337A KR1020227039288A KR20227039288A KR20220166337A KR 20220166337 A KR20220166337 A KR 20220166337A KR 1020227039288 A KR1020227039288 A KR 1020227039288A KR 20227039288 A KR20227039288 A KR 20227039288A KR 20220166337 A KR20220166337 A KR 20220166337A
Authority
KR
South Korea
Prior art keywords
aptamer
seq
receptor
cov
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039288A
Other languages
English (en)
Korean (ko)
Inventor
아네카트린 하베를란트
요하네스 뮐러
게르트 발루카트
페터 괴텔
Original Assignee
베를린 큐어스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베를린 큐어스 게엠베하 filed Critical 베를린 큐어스 게엠베하
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of KR20220166337A publication Critical patent/KR20220166337A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020227039288A 2020-04-09 2021-04-09 코로나비리대 감염을 치료하는데 사용하기 위한 앱타머 Pending KR20220166337A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20168929.6 2020-04-09
EP20176023 2020-05-22
EP20176023.8 2020-05-22
EP20180781.5 2020-06-18
EP20180781 2020-06-18
EP20204036 2020-10-27
EP20204036.6 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (1)

Publication Number Publication Date
KR20220166337A true KR20220166337A (ko) 2022-12-16

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039288A Pending KR20220166337A (ko) 2020-04-09 2021-04-09 코로나비리대 감염을 치료하는데 사용하기 위한 앱타머

Country Status (11)

Country Link
US (1) US12606828B2 (https=)
EP (1) EP4133083A1 (https=)
JP (1) JP2023521361A (https=)
KR (1) KR20220166337A (https=)
CN (1) CN115768895A (https=)
AU (1) AU2021252151A1 (https=)
BR (1) BR112022020439A2 (https=)
CA (1) CA3175067A1 (https=)
IL (1) IL297155A (https=)
MX (1) MX2022012618A (https=)
ZA (1) ZA202212179B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118210A (ko) * 2023-01-25 2024-08-05 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170931A (ko) * 2021-04-09 2023-12-19 베를린 큐어스 게엠베하 코로나바이러스 감염 치료에 사용하기 위한 압타머

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP0208A (xx) * 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
CN117653654A (zh) * 2016-11-23 2024-03-08 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118210A (ko) * 2023-01-25 2024-08-05 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Also Published As

Publication number Publication date
US20230140490A1 (en) 2023-05-04
ZA202212179B (en) 2025-03-26
CA3175067A1 (en) 2021-10-14
US12606828B2 (en) 2026-04-21
EP4133083A1 (en) 2023-02-15
IL297155A (en) 2022-12-01
JP2023521361A (ja) 2023-05-24
AU2021252151A1 (en) 2022-12-08
CN115768895A (zh) 2023-03-07
BR112022020439A2 (pt) 2022-11-29
MX2022012618A (es) 2022-11-07

Similar Documents

Publication Publication Date Title
CA3013683C (en) Oligonucleotides for reduction of pd-l1 expression
JP7267689B2 (ja) 自己抗体関連疾患に対する使用のためのアプタマー
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
US12606828B2 (en) Aptamers for use in the treatment of Coronaviridae infections
JP2026021387A (ja) コロナウイルス科感染の治療において使用するためのアプタマー
WO2021205012A1 (en) Aptamers for use in the treatment of coronaviridae infections
EP4605008A1 (en) Alpha-v beta-6 integrin ligands for extrahepatic delivery
JP6368363B2 (ja) デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物
HK40104624A (en) Aptamers for use in the treatment of coronaviridae infections
HK40104624B (en) Aptamers for use in the treatment of coronaviridae infections
EP2988773A2 (en) Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections
US20220089642A1 (en) Fc Receptor-ACE2 Conjugates and Use Thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902